Skip to main content
30.1 MCED
ScienceAllArticleYARN

MCED Tests: What Multi-Cancer Early Detection Means and How These Tests Compare

MCED tests aim to flag signals from many cancers in a single blood draw. This guide explains how they work, how Galleri, CancerSEEK and Cancerguard differ, and what a positive result means for you.

Published:
Updated:

Key Takeaways

  • MCED (multi-cancer early detection) tests are blood tests that aim to pick up a cancer signal from several types of cancer in one sample [1]. They're a category, not a single product.
  • Galleri is probably the one you've heard of, but it isn't the only one. CancerSEEK was described in a 2018 research paper [2]. Cancerguard is offered in the United States as a lab-developed test [3].
  • These tests are meant to sit alongside your regular screening, not replace it [4][5].
  • In the NHS-Galleri trial, which followed 142,250 people aged 50 to 77 in England, the test did not reduce stage III and IV cancers combined across 12 prespecified cancer types [1][6]. Fewer stage IV cancers were diagnosed in the group offered the test, but longer follow-up is needed to know whether that leads to better outcomes [1].
  • A positive result is not a diagnosis [4][5]. In that trial, 937 of 1,801 positive results (52%) were found to be cancer [6].
  • In the EU, a test like this must be CE marked unless an exception applies, such as an in-house test made by a health institution [7]. As of May 2026, no country had put a multi-cancer test into an organised screening programme [8].

You heard "screen for over 50 cancers." Here's what that actually means.

Picture an email from your employer offering a blood test that, it says, can "screen for over 50 cancers." Your first question is probably the one most people ask: is this real, or a scam? That question sits underneath almost every conversation about MCED tests, short for multi-cancer early detection. The technology is real. Whether it saves lives is still an open question [1][6].

So let's slow down and look at the whole picture: what multi-cancer early detection means, how the leading tests compare, where they sit next to the screening you already get, and what nobody knows yet. I'm not here to sell you a test or scare you off one. This is what you'd want a knowledgeable friend to tell you before you spend any money.

What Does MCED Mean?

MCED stands for multi-cancer early detection. The idea is easy to say and hard to pull off: one blood draw, checked for signals from several cancers, in people who have no symptoms [4].

These tests look for traces of cancer in the blood. Depending on the test, that can mean DNA changes, methylation patterns (chemical changes to DNA), DNA fragmentation patterns, protein levels or antibodies [4]. When the lab finds a pattern that looks like cancer, it reports a "cancer signal" [1][9].

The test isn't reading your whole body the way a scan does. It's reading your blood for clues.

Age matters. NHS-Galleri, the large trial in England, recruited people aged 50 to 77 [1]. That's the group the evidence speaks to.

MCED vs. MCD: Why You'll See Both Terms

If you read around, you'll meet a second acronym: MCD, for multi-cancer detection. The US National Cancer Institute (NCI) uses that term, while some researchers and companies prefer MCED [4]. Both refer to the same type of test, one meant to detect cancer in people with no symptoms [4].

One note on the NCI: it's an American body, so where I cite it, the guidance is US-derived and European recommendations may differ in the details. If you searched for one term and landed on a page using the other, you're in the right place.

Read next · ScienceThe Galleri Test Explained: Who It's For, How It Works, and What the Results MeanGalleri looks for a shared signal of more than 50 cancers in one blood sample. This guide explains how the test works, what England's NHS trial found, what a positive result means and what to ask your doctor.

How MCED Tests Differ from Traditional Cancer Screening

Think about the screening you may already know. Here is what the EU's cancer screening recommendation says for three cancers:

  • Breast cancer: mammography for women aged 50 to 69, with 45 to 74 suggested [10].
  • Cervical cancer: HPV testing for women aged 30 to 65 [10].
  • Bowel (colorectal) cancer: a stool test called FIT for people aged 50 to 74, with colonoscopy to follow up a positive result [10].

Each of these tests is built to find a single cancer. For lung, prostate and stomach cancer, the recommendation goes less far. On the basis of further research, it invites member states to look at low-dose CT for people at high risk of lung cancer, organised PSA screening with MRI follow-up for prostate cancer, and screen-and-test strategies for Helicobacter pylori in countries and regions with high stomach cancer incidence and mortality [10].

MCED turns that around. Instead of going deep on one cancer, it goes wide: one sample, many cancers [1]. That breadth is the whole appeal.

Why does breadth matter? The NCI says more than half of cancer deaths involve cancers that have no recommended screening test, including highly deadly ones such as ovarian and pancreatic cancer [4]. That comes from a US body, so read it as an American picture, but the gap is visible in Europe too: pancreatic and ovarian cancer aren't among the cancers named in the Commission's summary of its screening recommendation [10]. A test that could flag even some of these cancers earlier would fill a real gap.

The trade-off is easy to state. A test built around one cancer only has to be good at that one disease. A test built to look for many cancers has to cover more ground from one sample, and none of them screens for every type of cancer [4].

What MCED Tests Can and Can't Tell You

An MCED test screens. It doesn't diagnose. That distinction is the most important thing to understand before you take one.

A positive result means the test picked up a signal that might be cancer, and it leads to more testing [4]. It isn't a verdict. A negative result is reassuring, but it isn't a clean bill of health, because these tests miss cancers too: in NHS-Galleri, around a third of the people who had cancer got a positive result [9]. If you notice a new lump or a symptom that won't go away, a negative MCED result is no reason to wait.

Here's how to keep that straight in practice.

✓ Do✗ Don't
Keep up with your recommended standard screening on scheduleTreat an MCED test as a swap for your mammogram, bowel screening or cervical screening
Talk through any result with your doctor before you act on itAssume a positive result means you have cancer
Weigh the cost of the test and the follow-up before you order oneSkip a worrying symptom just because a test came back negative
Ask which specific cancers the test targetsExpect it to catch everything

The Leading MCED Tests Compared

Looking at the tests side by side helps, because once you see that several of them use different methods, the whole field makes more sense.

These tests don't all work the same way, and they don't all look for the same cancers [4]. Knowing the differences helps you ask better questions if you're thinking about one.

Galleri (GRAIL)

The Galleri test is made by GRAIL, which is why you'll also see it called the GRAIL test [11]. It's probably the one you've heard of. It looks for patterns in DNA circulating in the blood and, when it detects a cancer signal, predicts the part of the body where that signal most likely started [1].

GRAIL says the test can screen for 50 or more cancers [11]. In a 2021 validation study, whose authors include researchers affiliated with GRAIL, cancer signals were detected across more than 50 cancer types [12]. The same study found that the test picked up 16.8% of stage I cancers and 90.1% of stage IV cancers (its sensitivity at each stage), so it was much better at spotting advanced cancers than early ones [12].

GRAIL's own patient website says its information is intended for audiences in the United States only [11]. In England, Galleri has been tested in the NHS-Galleri trial [1]. If anyone offers you Galleri where you live, ask which regulatory route it uses (more on that below). For a closer look at this one test, our guide on The Galleri Test Explained: Who It's For, How It Works, and What the Results Mean goes through who it's aimed at and how to read a result.

CancerSEEK and Cancerguard

Galleri isn't the only approach. A 2018 paper in the journal Science described CancerSEEK, a test that combines two kinds of signal: levels of circulating proteins and mutations in cell-free DNA [2]. The researchers tested it on 1,005 people with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, oesophagus, colorectum, lung or breast, and only 7 of 812 healthy controls scored positive [2]. Those cancers had already been detected clinically, so this was a study in people with known cancer, not a screening trial [2].

Cancerguard comes from Exact Sciences. The company launched it as a laboratory-developed test in the United States [3]. It says the test can detect more than 50 cancer types and subtypes [3].

The takeaway isn't that one method beats another. Each test looks for its own group of cancers, and none screens for every type [4]. "Multi-cancer" does not mean "every cancer."

How These Tests Stack Up

TestWhat it looks atCancers it targetsWhere it stands
Galleri (GRAIL)Patterns in DNA circulating in the blood [1]More than 50 cancer types in a 2021 validation study [12]Tested in the NHS-Galleri trial in England [1]; the maker's patient site is for US audiences [11]
CancerSEEKCirculating proteins plus mutations in cell-free DNA [2]Eight common cancer types in the 2018 study [2]Described in a 2018 research paper [2]
Cancerguard (Exact Sciences)Several classes of biomarker, according to the company [3]More than 50 cancer types and subtypes, according to the company [3]Launched as a lab-developed test in the United States [3]

One caveat on that table. These details change as new trial data comes out and as companies update their products. Treat it as a snapshot, and confirm the current details with the test maker or your doctor before you rely on any of it.

30.2 MCED

Blood-Based Tests for Specific Cancers (Breast and Pancreatic)

There's a second category worth keeping apart from MCED: blood tests built to look for one cancer, not many.

The logic is different. A test aimed at a single disease only has to be good at that one disease.

Breast Cancer Screening Blood Tests

A breast cancer screening blood test sounds like it could replace the mammogram nobody enjoys. For screening, though, the EU recommendation names mammography, for women aged 50 to 69, with 45 to 74 suggested [10]. If you're invited for a mammogram, go. If a clinic or website offers you a blood test instead, ask what evidence supports it and whether any screening guideline recommends it.

Pancreatic Cancer Screening Blood Tests

Pancreatic cancer shows why people want these tests. The NCI lists it among the highly deadly cancers that have no recommended screening test [4]. A reliable pancreatic cancer screening blood test would matter a great deal. But if someone offers you one today, ask what evidence it rests on and what happens after a positive result.

MCED Tests vs. Standard Screenings: Which Comes First?

If you take one message from this article, make it this: for cancers that already have a recommended screening test, that test stays first. The NCI says standard screening is recommended whether or not you have an MCED test [4]. Cancer Research UK's page on the test tells people to consider screening when they're invited, whether or not they're part of the research [5].

In the EU, those tests are mammography, HPV testing and FIT, with lung, prostate and stomach screening still being explored [10]. So standard screening remains your main tool, and an MCED test, if you choose one, would be an addition, not a swap. If you're not sure which screenings you're due for, our guide on What Cancer Screenings Should You Get? A Practical Guide by Age, Sex, and Risk explains them in more detail.

Think of it as a wider net under the specific ones you already cast. You still get your mammogram and your bowel screening on schedule. The MCED test is there to maybe catch something in cancers that have no screening at all.

That's the case for MCED tests: not replacing what works, but reaching cancers where today we have nothing. Whether they deliver on it is exactly what trials like NHS-Galleri are testing.

What Happens If Your MCED Test Is Positive?

This is the scenario people don't think about until they're in it, and it's the part I'd most want a friend to walk me through in advance. A positive result starts a process. It doesn't end one.

The Follow-Up Pathway, Step by Step

  • Your result comes back showing a cancer signal. With Galleri, it also predicts the part of the body the signal most likely came from [1].
  • Your doctor arranges more tests, such as imaging, a tissue biopsy or, in some cases, surgery [4].
  • Those tests show whether a cancer is present. Getting that answer can take time and more than one test [4].

A positive result is far from a sure thing. In NHS-Galleri, 937 of the 1,801 positive results over three rounds (52%) were found to be cancer [6]. Fewer than 1 in 200 tests gave a false alarm [1]. Even so, about half of the positive results weren't linked to a cancer diagnosis [6]. A false alarm isn't free, either: the NCI lists anxiety, time and expense, and the risks of follow-up procedures among the harms [4].

None of that makes the tests useless. A positive result is the start of a question, not the answer, and it helps to know that before it lands in your inbox.

The Regulatory and Insurance Landscape

Let's talk about the rules and who pays, because that's where a lot of the confusion sits.

In the EU, tests that examine specimens such as blood from the human body are regulated as in vitro diagnostic devices under Regulation (EU) 2017/746, known as the IVDR [13]. A device like that has to be CE marked, or be made in-house by a health institution under Article 5(5), or be used in a performance study, or be exceptionally allowed a derogation from CE marking by a competent authority [7]. Member states can also restrict the manufacture and use of in-house devices, so what's allowed can differ from one country to the next [7].

What does that mean for you? Ask any clinic or company offering a multi-cancer blood test which of those routes its test uses, and ask to see it in writing.

Then there's the bill. As of May 2026, no country had put an MCED test into an organised screening programme [8]. If a clinic offers you a new cancer screening test like this, ask for the total price in writing, including any follow-up tests after a positive result, and ask your insurer whether any part would be covered.

What the NHS-Galleri Trial Just Told Us

England has now reported the results of a large randomised trial of an MCED test [1]. Peter Sasieni, Professor of Cancer Epidemiology at Queen Mary University of London, calls it the first randomised controlled trial anywhere to evaluate an MCED blood test at this scale [1]. NHS-Galleri recruited 142,250 people aged 50 to 77 and randomly assigned them either to an intervention group, whose blood was tested with the Galleri test, or to a control group receiving usual NHS care [1]. Participants were invited to give blood samples over three annual screening rounds [1]. The results were published in September 2026 in the New England Journal of Medicine and Nature Medicine [1].

The headline result is a miss. The trial did not meet its main goal, which was to reduce the combined number of stage III and IV cancers across 12 prespecified cancer types [1]. Underneath that sits a more mixed picture. Fewer stage IV cancers were diagnosed among people offered the test, but more stage III cancers were, and the one offset the other [6]. More cancers were found at stage I and II, and fewer were diagnosed after a visit to Accident and Emergency (A&E) [1].

The researchers say longer follow-up is needed to see how these differences develop and whether they translate into better outcomes [1]. The trial also wasn't powered to show whether the test reduces deaths from cancer [6].

On accuracy, about one in 100 people tested got a positive result in each round [1]. The test's specificity, which is how reliably it stays negative when there is no cancer, was around 99.5% to 99.6% [1]. And as noted above, around a third of the people who had cancer got a positive result [9].

One more thing worth knowing: GRAIL, the company behind Galleri, funded the trial [1][6]. The NHS and other health organisations will consider the evidence as they assess the potential future role of multi-cancer early detection testing [1].

What to Watch in the Next Few Years

I'll be upfront about the open questions. The science here is unfinished, and a confident answer in either direction would be getting ahead of the evidence.

The biggest unknown is whether finding cancer earlier with these tests means fewer people die of it. The UK National Screening Committee's position statements, as described in a University of Warwick release, say that early signals of benefit, such as fewer late-stage diagnoses, cannot replace deaths as the measure of whether a screening programme works [8]. The release also flags a concern that these tests may preferentially detect more aggressive cancers, which could make a programme look beneficial through fewer late-stage diagnoses without a matching drop in deaths [8].

Other questions stack up behind it. How often should you test? Who benefits most, and who just gets needless scares? What's the right move when a result is inconclusive? NHS-Galleri itself wasn't designed to assess different screening intervals [6]. Further analyses are planned, including longer-term follow-up [1].

Watch for those results. They'll tell you far more than any advert will.

30. 3 MCED

Talking to Your Doctor About MCED Testing

The decision to take an MCED test isn't really a yes or no. It's a fit question. It depends on your age, your risk, your budget and how you'd feel handling an uncertain result.

This is a decision to make with your doctor. You bring your values and your situation, they bring the medical picture, and together you work out whether testing makes sense for you. If the thought of a possible false alarm and a string of follow-up scans would wreck you, say so before you test, not after.

Questions to Ask Before You Test

  • Based on my age and risk factors, would I even be a good candidate?
  • Which specific cancers does this test look for, and how accurate is it for them?
  • Is the test CE marked, made in-house by a health institution, or offered as part of a study?
  • What's the total price, including follow-up tests, and will any part be covered?
  • If the result is positive, what happens next, and what will that cost me?
  • How does this fit with the screenings I'm already supposed to get?

Bring that list to your appointment. A good clinician will welcome it.

One Test in a Bigger Picture

So, back to that email from your employer: real, or a scam? Real. Multi-cancer early detection is a legitimate area of research, and one day it may help catch cancers that have no recommended screening today [4]. But the large NHS-Galleri trial did not show fewer stage III and IV cancers overall [6]. Whether the test saves lives isn't known yet [1][6]. And it isn't a replacement for the screening that already exists [4].

My advice: keep getting your recommended screening, whatever you decide. If MCED testing interests you, don't order one off a website on a whim. Take the questions above to your doctor and have the conversation.

If you're the one holding that email, the unglamorous move is probably the right first one: book the screening you've been putting off. An MCED test may become a sensible addition some day. For now, the recommended tests come first.

References

[1] Queen Mary University of London. (2026, September 23). Major NHS trial provides new evidence on multi-cancer blood test [News release]. https://www.qmul.ac.uk/news/latest-news/2026/medicine-and-dentistry/fmd/major-nhs-trial-provides-new-evidence-on-multi-cancer-blood-test.html

[2] Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., Hruban, R. H., Wolfgang, C. L., Goggins, M. G., Dal Molin, M., Wang, T. L., Roden, R., Klein, A. P., Ptak, J., Dobbyn, L., . . . Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 359(6378), 926-930. https://doi.org/10.1126/science.aar3247

[3] Exact Sciences Corp. (n.d.). Exact Sciences launches Cancerguard™, first-of-its-kind multi-cancer early detection blood test [Press release]. Business Wire. https://www.businesswire.com/news/home/20250910938880/en/Exact-Sciences-Launches-Cancerguard-First-of-Its-Kind-Multi-Cancer-Early-Detection-Blood-Test

[4] National Cancer Institute, Division of Cancer Prevention. (n.d.). Questions and answers about multi-cancer detection tests. Retrieved November 15, 2026, from https://prevention.cancer.gov/research-areas/networks-consortia-programs/csrn/q-a-about-mcd-tests

[5] Cancer Research UK. (2025, May 29). Galleri blood test. Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/tests-and-scans/blood-tests/galleri-blood-test

[6] Sasieni, P., Johnson, P., Round, T., Warwick, J., Jones, H., Dolly, S., Lee, L., Lee, Y., Kumar, H., Liang, W., Smittenaar, R., Neal, R. D., & Swanton, C. (2026). Effect of screening with multicancer early-detection test on late-stage cancer diagnosis. New England Journal of Medicine, 395(14), 1374-1386. https://doi.org/10.1056/NEJMoa2505723

[7] Medical Device Coordination Group. (2023, January). Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 (MDCG 2023-1). https://health.ec.europa.eu/system/files/2023-01/mdcg_2023-1_en.pdf

[8] University of Warwick. (2026, May 26). Warwick researchers help shape new national guidance for cancer screening [Press release]. https://warwick.ac.uk/news/pressreleases/warwick-researchers-help-shape-national-guidance-for-cancer-screening/

[9] NHS-Galleri Trial. (2026, September 23). First full results from the NHS-Galleri trial published in leading journals [Trial update]. https://www.nhs-galleri.org/trial-updates/first-full-nhs-galleri-results-published-in-leading-journals

[10] European Commission. (2022, December 9). European Health Union: Commission welcomes adoption of new EU cancer screening recommendations (Press release IP/22/7548). https://ec.europa.eu/commission/presscorner/api/files/document/print/en/ip22_7548/IP_22_7548_EN.pdf

[11] GRAIL, Inc. (n.d.). What blood test shows cancer signal? | Galleri® [Patient information]. Retrieved November 15, 2026, from https://www.galleri.com/patient

[12] Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., & Liu, M. C. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167-1177. https://doi.org/10.1016/j.annonc.2021.05.806

[13] Medical Device Coordination Group. (2024, October). Guidance on qualification of in vitro diagnostic medical devices (MDCG 2024-11). https://health.ec.europa.eu/document/download/12b92152-371f-404d-a865-93800cd5cdcaen?filename=mdcg_2024-11_en.pdf

This article is for educational purposes only and is not medical advice. Always consult your doctor or another qualified healthcare professional for guidance specific to your situation.

YARN project logo

This content was created during the YARN project, co-funded under the EU4Health Programme in 2025-2028 (Grant Agreement No. 101219053).

Continue reading · ScienceThe Galleri Test Explained: Who It's For, How It Works, and What the Results MeanGalleri looks for a shared signal of more than 50 cancers in one blood sample. This guide explains how the test works, what England's NHS trial found, what a positive result means and what to ask your doctor.